## Abstract CD40, a member of the tumour necrosis factor family, is expressed in a variety of epithelial cells. Although soluble CD40 agonists are growth‐inhibitory, membrane‐presented CD40 ligand (CD40L) induces extensive apoptosis in carcinoma cells. This study investigated whether CD40 is expres
Destination ‘Lysosome’: a target organelle for tumour cell killing?
✍ Scribed by Roberta Castino; Marina Démoz; Ciro Isidoro
- Book ID
- 102373349
- Publisher
- John Wiley and Sons
- Year
- 2003
- Tongue
- English
- Weight
- 329 KB
- Volume
- 16
- Category
- Article
- ISSN
- 0952-3499
- DOI
- 10.1002/jmr.643
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Lysosomes and lysosome‐related organelles constitute a system of acid compartments that interconnect the inside of the cell with the extracellular environment via endocytosis, phagocytosis and exocytosis. In recent decades it has been recognized that lysosomes are not just wastebaskets for disposal of unused cellular constituents, but that they are involved in several cellular processes such as post‐translational maturation of proteins, degradation of receptors and extracellular release of active enzymes. By complementing the autophagic process, lysosomes actively contribute to the maintenance of cellular homeostasis. Proteolysis by lysosomal cathepsins has been shown to mediate the death signal of cytotoxic drugs and cytokines, as well as the activation of pro‐survival factors. Secreted lysosomal cathepsins have been shown to degrade protein components of the extracellular matrix, thus contributing actively to its re‐modelling in physiological and pathological processes. The malfunction of lysosomes can, therefore, impact on cell behaviour and fate. Here we review the role of lysosomal hydrolases in several aspects of the malignant phenotype including loss of cell growth control, altered regulation of cell death, acquisition of chemoresistance and of metastatic potential. Based on these observations, the lysosome is proposed as a potential target organelle for the chemotherapy of tumours. We will also present some recent data concerning the technologies for delivering chemotherapeutic drugs to the endosomal–lysosomal compartment and the strategies to improve their efficacy. Copyright © 2003 John Wiley & Sons, Ltd.
📜 SIMILAR VOLUMES
## Abstract ## Background We describe an __in vitro__ tumour model for targeted radiotherapy and gene therapy that incorporates cell population heterogeneity. ## Materials and methods Transfectant mosaic spheroids (TMS) and transfected mosaic monolayers (TMM) are composed of two cell populations